drugset / Trial / NCT05047133
Effect of Early Administration of TXA in Adult Hip Fractures
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2022-07-01
- Completion
- 2022-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tranexamic Acid | Small molecule | 1 g | Intravenous |
| Subject | Tranexamic Acid | Small molecule | 2 g | Intravenous |
Indications
No indication recorded.